Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients

We compared the antibody responses and persistence of the reduced-dose, 9 µg hemagglutinin (HA)/strain intradermal (ID) injection via the Mantoux technique and the 15 μg HA/strain intramuscular (IM) injection of the repeated annual identical trivalent, inactivated, split-virion vaccine 2011–2012 in...

Full description

Bibliographic Details
Main Authors: Benjamas Chuaychoo, Uraiwan Kositanont, Parichat Niyomthong, Nuttapol Rittayamai, Sorachai Srisuma, Kanokwan Rattanasaengloet, Walaiporn Wongsrisakunkaew, Julalux Thongam, Thaweesak Songserm
Format: Article
Language:English
Published: Taylor & Francis Group 2020-06-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:http://dx.doi.org/10.1080/21645515.2019.1692559
_version_ 1827809601965260800
author Benjamas Chuaychoo
Uraiwan Kositanont
Parichat Niyomthong
Nuttapol Rittayamai
Sorachai Srisuma
Kanokwan Rattanasaengloet
Walaiporn Wongsrisakunkaew
Julalux Thongam
Thaweesak Songserm
author_facet Benjamas Chuaychoo
Uraiwan Kositanont
Parichat Niyomthong
Nuttapol Rittayamai
Sorachai Srisuma
Kanokwan Rattanasaengloet
Walaiporn Wongsrisakunkaew
Julalux Thongam
Thaweesak Songserm
author_sort Benjamas Chuaychoo
collection DOAJ
description We compared the antibody responses and persistence of the reduced-dose, 9 µg hemagglutinin (HA)/strain intradermal (ID) injection via the Mantoux technique and the 15 μg HA/strain intramuscular (IM) injection of the repeated annual identical trivalent, inactivated, split-virion vaccine 2011–2012 in chronic obstructive pulmonary disease (COPD) patients. Eighty patients were randomized to ID (n = 41) and IM (n = 39) groups. Four weeks post-vaccination, the antibody responses of the two groups were similar; those for influenza A(H1N1)pdm09 and influenza A(H3N2)–but not influenza B–met the criteria of the Committee for Proprietary Medicinal Products (CPMP). The antibody responses for influenza A(H1N1)pdm09 rapidly declined in both groups, especially with the ID injection, whereas those for influenza A(H3N2) maintained above the CPMP criteria throughout 12 months post-vaccination. The geometric mean titres for influenza A(H1N1)pdm09 persisted above the protective threshold (≥ 40) until 6 months post-vaccination in both the ID and IM groups. The seroprotection rates of the ID and IM groups were above 60% until 3 months and 6 months post-vaccination, respectively. In conclusion, the 9 μg HA/strain ID injection of vaccine 2011–2012 elicited antibody responses similar to the standard dose of 15 μg of the HA/strain IM injection at 4 weeks post-vaccination. However, the antibody responses for influenza A(H1N1)pdm09 rapidly declined, especially in the case of the ID injection, whereas they were comparable for influenza A(H3N2). Additional strategies for increasing vaccine durability should be considered, especially for new pandemic strains affecting elderly COPD patients.
first_indexed 2024-03-11T22:43:48Z
format Article
id doaj.art-7ba8bf881a9d4f918f46e55c95cf3b74
institution Directory Open Access Journal
issn 2164-5515
2164-554X
language English
last_indexed 2024-03-11T22:43:48Z
publishDate 2020-06-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj.art-7ba8bf881a9d4f918f46e55c95cf3b742023-09-22T08:45:34ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-06-011661371137910.1080/21645515.2019.16925591692559Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patientsBenjamas Chuaychoo0Uraiwan Kositanont1Parichat Niyomthong2Nuttapol Rittayamai3Sorachai Srisuma4Kanokwan Rattanasaengloet5Walaiporn Wongsrisakunkaew6Julalux Thongam7Thaweesak Songserm8Faculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj Hospital, Mahidol UniversityFaculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj HospitalFaculty of Medicine Siriraj Hospital, Mahidol UniversityKasetsart UniversityWe compared the antibody responses and persistence of the reduced-dose, 9 µg hemagglutinin (HA)/strain intradermal (ID) injection via the Mantoux technique and the 15 μg HA/strain intramuscular (IM) injection of the repeated annual identical trivalent, inactivated, split-virion vaccine 2011–2012 in chronic obstructive pulmonary disease (COPD) patients. Eighty patients were randomized to ID (n = 41) and IM (n = 39) groups. Four weeks post-vaccination, the antibody responses of the two groups were similar; those for influenza A(H1N1)pdm09 and influenza A(H3N2)–but not influenza B–met the criteria of the Committee for Proprietary Medicinal Products (CPMP). The antibody responses for influenza A(H1N1)pdm09 rapidly declined in both groups, especially with the ID injection, whereas those for influenza A(H3N2) maintained above the CPMP criteria throughout 12 months post-vaccination. The geometric mean titres for influenza A(H1N1)pdm09 persisted above the protective threshold (≥ 40) until 6 months post-vaccination in both the ID and IM groups. The seroprotection rates of the ID and IM groups were above 60% until 3 months and 6 months post-vaccination, respectively. In conclusion, the 9 μg HA/strain ID injection of vaccine 2011–2012 elicited antibody responses similar to the standard dose of 15 μg of the HA/strain IM injection at 4 weeks post-vaccination. However, the antibody responses for influenza A(H1N1)pdm09 rapidly declined, especially in the case of the ID injection, whereas they were comparable for influenza A(H3N2). Additional strategies for increasing vaccine durability should be considered, especially for new pandemic strains affecting elderly COPD patients.http://dx.doi.org/10.1080/21645515.2019.1692559influenza vaccineintradermalinfluenza a(h1n1)pdm09immunogenicityrepeated identical vaccineantibody persistencecopd
spellingShingle Benjamas Chuaychoo
Uraiwan Kositanont
Parichat Niyomthong
Nuttapol Rittayamai
Sorachai Srisuma
Kanokwan Rattanasaengloet
Walaiporn Wongsrisakunkaew
Julalux Thongam
Thaweesak Songserm
Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
Human Vaccines & Immunotherapeutics
influenza vaccine
intradermal
influenza a(h1n1)pdm09
immunogenicity
repeated identical vaccine
antibody persistence
copd
title Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
title_full Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
title_fullStr Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
title_full_unstemmed Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
title_short Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients
title_sort comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post pandemic 2011 2012 in copd patients
topic influenza vaccine
intradermal
influenza a(h1n1)pdm09
immunogenicity
repeated identical vaccine
antibody persistence
copd
url http://dx.doi.org/10.1080/21645515.2019.1692559
work_keys_str_mv AT benjamaschuaychoo comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT uraiwankositanont comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT parichatniyomthong comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT nuttapolrittayamai comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT sorachaisrisuma comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT kanokwanrattanasaengloet comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT walaipornwongsrisakunkaew comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT julaluxthongam comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients
AT thaweesaksongserm comparisonofimmunogenicitybetweenintradermalandintramuscularinjectionsofrepeatedannualidenticalinfluenzavirusstrainspostpandemic20112012incopdpatients